Malaysian Genomics to Distribute Genetic Screening Tests in Singapore

Group continues focus on diversifying access across geographical markets

PETALING JAYA (11 JULY  2023) – Malaysian Genomics Resource Centre Berhad (“Malaysian Genomics” or “the Group”; Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group’s wholly-owned subsidiary, MGRC Healthcare Sdn Bhd (“MGRC-H”), has entered into a supply agreement with DLF Engineering Pte Ltd (“DLF”) for the distribution of genetic screening tests and cell laboratory production services in Singapore.  

DLF is a diversified engineering services and trade distribution company with an integrated supply-chain network of private and public healthcare physicians, aesthetics and wellness centres, as well as insurance and employee-benefits providers in Singapore. MGRC-H is a genomics and biopharmaceutical specialist with a range of healthcare products including genetic screening tests, compounded supplements and cell laboratory production services for mesenchymal stem cells, NK cells, exosomes, and functional cosmeceuticals.

Mr. Azri Azerai, Executive Chairman of Malaysian Genomics, said, “The supply agreement with DLF ties in nicely with the Group’s strategy of diversifying geographically and in respect to customer base. We are delighted to have this partnership with DLF and look forward to further collaborations.”

“Aside from genetic screening tests and cell products, we are looking to bring in more and registering said products in Singapore. Together, we will continue to strengthen our reach in Singapore and throughout Southeast Asia”

Fan Dexter, Head of Healthcare & Wellness Engineering Services of DLF Group, said, “We are thrilled to be collaborating with Malaysian Genomics for DLF’s strategic foray into modern healthcare encompassing the synergy of genomics with primary healthcare and general wellness. MGRC is building an extensive geographical network across Asia and we are glad to be the esteemed Singapore partner of its products and services as this partnership complements our overarching vision of providing health and wellness to all throughout a person’s life stages and senescence. “

Malaysian Genomics had earlier, in May 2023, entered into a strategic cooperation agreement with Toticell Limited, a Dhaka, Bangladesh-based regenerative healthcare specialist focusing on treatments for musculoskeletal conditions such as arthritis, sports-related injuries and tendinopathies.